Combination of a single dose anti-cd20 antibody and bortezomib    (DrugBank: Bortezomib)

1 disease
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia1

61. Autoimmune hemolytic anemia    [ 90 clinical trials,   72 drugs,   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways]
Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 90 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04083014
(ClinicalTrials.gov)
August 20, 201931/8/2019Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaAn Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia;Autoimmune Hemolytic Anemia and Autoimmune ThrombocytopeniaDrug: combination of a single dose anti-CD20 antibody and bortezomibPeking Union Medical College HospitalNULLRecruiting18 Years80 YearsAll43Phase 2China